Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China · Delayed Price · Currency is CNY 21.23
-0.80 (-3.63%)
At close: Sep 10, 2026
Enwei Pharmaceutical Revenue
Enwei Pharmaceutical had revenue of 199.25M CNY in the quarter ending June 30, 2026, a decrease of -21.16%. This brings the company's revenue in the last twelve months to 826.13M, down -5.39% year-over-year. In the year 2025, Enwei Pharmaceutical had annual revenue of 900.77M with 10.91% growth.
Revenue (ttm)
826.13M
Revenue Growth
-5.39%
P/S Ratio
2.72
Revenue / Employee
550.39K
Employees
1,501
Market Cap
2.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 900.77M | 88.64M | 10.91% |
| Dec 31, 2024 | 812.13M | 26.94M | 3.43% |
| Dec 31, 2023 | 785.19M | 93.62M | 13.54% |
| Jan 1, 2023 | 691.57M | 11.88M | 1.75% |
| Jan 1, 2022 | 679.70M | 45.54M | 7.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Anhui Huangshan Capsule | 407.10M |
| Guhan Pharmaceutical Group | 329.41M |
| Qinghai Spring Medicinal Resources Technology | 303.67M |